From molecule to patient

The journey that transforms a molecule into a medicine that improves patient outcomes takes years of work, billions in investments, and decisions made in uncertain circumstances. With so much at stake, it’s essential for organisations to find ways to make better, evidence-led decisions earlier.

AI and advanced analytics are now an integral part of the molecule to patient journey. Organisations are now facing the challenge of turning the intelligence generated by these tools into better decisions earlier. Not only that, but these decisions also need to be supported with enough trust, governance, and accountability as they scale, to ensure that the right molecule reaches the right patient sooner.

At PwC, our experts have experience in guiding organisations on their journeys from developing molecules to improving patient outcomes. We share this knowledge in our whitepaper, explaining how organisations can use intelligence to make better decisions, build intelligence into their development strategy, and learn throughout the medicine’s lifecycle.